Ultraniskodawkowa doustna menopauzalna terapia hormonalna – niezrealizowane marzenie czy wreszcie rzeczywisto ?

Reduction of estrogen and progestogen doses is one of the main trends in oral menopausal hormonetherapy (MHT). Studies on ultra low oral MHT, composed of 0,5 mg estradiol plus reduced doses of variousprogestoagens (e.g. norethisterone acetate, dydrogesterone), revealed both its high safety profile as well astherapeutic efficacy in alleviating of numerous aliments of the menopausal period.